Last edition
News about "KCNT1-related epilepsy"
Jazz Pharmaceuticals Acquires Actio Biosciences
Jazz Pharmaceuticals acquires ABS-1230, a first-in-class precision therapy for KCNT1-related epilepsy, strengthening its rare disease pipeline.
KCNT1-related Epilepsy | 16/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members